Insulet Expands Omnipod U.S. Recycling Program, Diverting Millions of Pods from Landfills and Creating a More Sustainable Future

Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod brand of products, has announced the expansion of its U.S. Pod recycling program, which is now available to all U.S. customers.

“Here at Insulet, our mission is to transform the lives of people with diabetes, and we are equally committed to creating a more sustainable future,” said Carolyn Sleeth, Senior Vice President and U.S. General Manager. “We are proud of the success achieved through our Massachusetts and California Pod recycling pilot programs, which began in 2022 and 2024, and we are excited to now offer Pod recycling to all U.S. customers, reducing waste and minimizing our environmental impact.”

The Pod recycling program is offered at no cost to customers, who can request a Pod recycling kit online to return their used Pods. The returned Pods are decontaminated and then transported to a company specializing in recycling for electronics and medical products, ultimately minimizing landfill waste and advancing Insulet’s commitment to circular solutions.

“Reducing waste is a key priority for our Company, and I’m thrilled that our program is now available nationwide,” said Lisa Brady, Vice President and Chief Sustainability Officer. “We’ve made it easy for customers to help advance this objective of our Sustainability program and look forward to diverting millions more Pods from U.S. landfills.”

In the U.S., customers can seamlessly request a Pod recycling kit by completing an online request form. Outside of the U.S., Insulet has longstanding Pod takeback programs in many international markets where customers can request a Pod takeback kit by contacting their local Insulet Customer Support team.

About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit: insulet.com and omnipod.com.

2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251215704196/en/

The Insulet Stock at the time of publication of the news with a raise of +1,19 % to 254,8USD on Tradegate stock exchange (15. Dezember 2025, 11:39 Uhr).